Clin2
NCT06982196Possibly a fitEnrolling by invitation

Sulodexide to prevent psoriasis return after stopping biologic

Psoriasis (PsO)Randomised Controlled Trial

Part of Skin clinical trials.

This trial tests if sulodexide, a medication that helps blood flow, can keep psoriasis from coming back after you have stopped using a biologic drug (such as strychnicolizumab) because your skin was completely clear for 6 months.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
160 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are between 18 and 65 years old.
  • You have moderate to severe plaque psoriasis.
  • You have taken a biologic called strychnicolizumab for at least 3 months, your skin became fully clear, and you have stayed clear for 6 months while on the biologic.
  • You are now ready to stop the biologic according to standard guidelines.
  • You have not had a serious infection or bleeding disorder recently.
  • You are not pregnant, planning pregnancy, or breastfeeding during the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07642544Not yet recruiting
Comparing long-term secukinumab dosing schedules for psoriasis

This study looks at how different ways of taking secukinumab (Cosentyx) over the long term affect skin clearance in people with moderate-to-severe psoriasis. It tries to find which dosing schedule keeps skin clear best over time.

Nanjing, Jiangsu
NCT06592274Recruiting· Phase 2
Study of HB0017 for people with plaque psoriasis

This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.

Bengbu, Anhui
NCT04239859Not yet recruiting· Phase 4
Secukinumab for moderate to severe plaque psoriasis

This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.

Outram Park
NCT06398106Recruiting· Phase 4
Proactive monitoring vs. standard use of biologics for psoriasis

This study compares a proactive approach (adjusting drug levels based on regular blood tests) versus the usual way of using biologics for psoriasis. It helps see if active monitoring can improve treatment while keeping you safe.

Bruges
NCT04537689Recruiting· Phase 4
Test ixekizumab and stopping it in plaque psoriasis

This study looks at how well ixekizumab (an injection medication) works for moderate-to-severe plaque psoriasis, and what happens when the treatment is withdrawn. It may help you learn whether stopping the medicine is safe and how skin disease outcomes change over time.

Outram Park
NCT03254667Enrolling by invitation
Track outcomes in adults with moderate-to-severe psoriasis

This study keeps track of how people with moderate-to-severe psoriasis do over time while using Siliq or other approved treatments. It may help researchers understand how treatments compare in real life.

Bridgewater, New Jersey

Hear when a new Psoriasis (PsO) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.